



149th GENERAL ASSEMBLY
FISCAL NOTE

BILL: HOUSE BILL NO. 386
SPONSOR: Representative Baumbach
DESCRIPTION: AN ACT TO AMEND TITLE 18, TITLE 29, AND TITLE 31 OF THE DELAWARE CODE RELATING TO COVERAGE FOR TREATMENT OF PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH STREPTOCOCCAL INFECTIONS AND PEDIATRIC ACUTE ONSET NEUROPSYCHIATRIC SYNDROME.

Assumptions:

1. This Act shall take effect upon signature of the Governor.
2. This Act seeks to amend Title 18, Title 29, and Title 31 of the Delaware Code related to coverage for treatment of Pediatric Autoimmune Neuropsychiatric Disorders (PANDAS) associated with Streptococcal Infections and Pediatric Acute Onset Neuropsychiatric Syndrome (PANS).
3. This Act requires all individual, group, State employee, and public assistance insurance plans to provide coverage for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome.
4. According to the Statewide Benefits Office, Highmark reports a potential 9 State of Delaware covered members diagnosed from the universe population of 18,000 members. In addition, the Statewide Benefits Office assumes an additional 1 member to be covered under Aetna who would be diagnosed with a case requiring IVIG Therapy. This treatment costs, on average, \$10,000 per infusion. Factors adjusting this total include inpatient/outpatient costs for infusion, prescription costs per gram of the medication (\$100 to \$350 per gram), terms of frequency, and doses per year. This estimate may vary on a patient case by case basis. Assuming one round of the therapy, per eligible member, would cost an estimated total of \$100,000.

State Eligible Plans: 10 members X \$10,000 ≈ \$100,000

Cost: Group Health Insurance Plan

Fiscal Year 2019:	\$100,000
Fiscal Year 2020:	\$100,000
Fiscal Year 2021:	\$100,000

Prepared by Victoria Brennan
Office of the Controller General